Patents by Inventor Louis Vignati

Louis Vignati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING METABOLIC DISORDERS AND OBESITY WITH GIP AND GLP-1 RECEPTOR-ACTIVE GLUCAGON-BASED PEPTIDES
    Publication number: 20160175400
    Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.
    Type: Application
    Filed: February 10, 2015
    Publication date: June 23, 2016
    Inventors: Louis Vignati, Richard D. DiMarchi
  • Methods for treating metabolic disorders and obesity with a peptide comprising the amino acid sequence of SEQ ID No. 146
    Patent number: 8975223
    Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: March 10, 2015
    Assignee: Marcadia Biotech, Inc.
    Inventors: Louis Vignati, Richard D. DiMarchi
  • METHODS FOR TREATING METABOLIC DISORDERS AND OBESITY WITH GIP AND GLP-1 RECEPTOR-ACTIVE GLUCAGON-BASED PEPTIDES
    Publication number: 20140018291
    Abstract: Methods are provided for administering an extended half-life GLP-1/GIP coagonist peptide to a patient in need thereof for reducing weight gain, inducing weight loss, treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels in said patient.
    Type: Application
    Filed: December 22, 2011
    Publication date: January 16, 2014
    Applicant: MARCADIA BIOTECH, INC.
    Inventors: Louis Vignati, Richard D. Dimarchi
  • Combination Methods for Preserving Visual Acuity
    Publication number: 20080234351
    Abstract: The present invention relates to a method for preserving the vision of a patient suffering from diabetic retinopathy which comprises administering to said patient an effective amount of ruboxistaurin or a pharmaceutical salt thereof wherein said administration is in conjunction with focal or grid laser photocoagulation therapy.
    Type: Application
    Filed: September 18, 2006
    Publication date: September 25, 2008
    Inventors: Matthew John Sheetz, Louis Vignati, Xin Zhi
  • Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
    Patent number: 7223728
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Grant
    Filed: October 6, 2003
    Date of Patent: May 29, 2007
    Assignee: Eli Lilly and Company
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Louis Vignati
  • Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
    Publication number: 20040127414
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used, in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associate with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Application
    Filed: October 6, 2003
    Publication date: July 1, 2004
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, William Terry Johnson, Louis Vignati
  • Therapeutic treatment for VEGF related diseases
    Patent number: 6284751
    Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the &bgr;-isozyme selective PKC inhibitor, (S)-3,4-[N,N′-1,1′-((2″-ethoxy)-3′″(O)-4′″-(N,N-dimethylamino)-butane)-bis-(3,3′-indolyl)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: September 4, 2001
    Assignee: Eli Lilly and Company
    Inventors: Lloyd P. Aiello, Michael R. Jirousek, George L. King, Louis Vignati, Douglas Kirk Ways
  • Therapeutic treatment for VEGF related ocular diseases
    Patent number: 6114320
    Abstract: A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: September 5, 2000
    Assignees: Eli Lilly and Company, Joslin Diabetes Center
    Inventors: Lloyd P. Aiello, Michael R. Jirousek, George L. King, Louis Vignati, Douglas Kirk Ways
  • Therapeutic treatment for skin disorders
    Patent number: 6093740
    Abstract: A method for reducing or inhibiting vascular permeability especially the increased vascular permeability associated with VPF/VEGF, and dermal edema exhibited with bullous phemigoid, erythema multiforme, dermatitis herpetiformis, contact dermatitis/delayed hypersensitivity is disclosed, particularly using the .beta.-isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione and its pharmaceutically acceptable salts.
    Type: Grant
    Filed: April 9, 1998
    Date of Patent: July 25, 2000
    Assignee: Eli Lilly and Company
    Inventors: Michael Robert Jirousek, Lawrence E. Stramm, Louis Vignati, Douglas Kirk Ways
  • Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
    Patent number: RE40876
    Abstract: Thiazolidinedione (TZD) and its pharmacologically active derivatives can be used in combination with agonists of glucagon-like peptide-1 (GLP-1), to treat non-insulin dependent diabetes mellitus, optionally with other therapies, by improving glycemic control while minimizing side effects, such as heart hypertrophy and elevated fed-state plasma glucose, which are associated with both TZD and GLP-1 monotherapies. Thus, the co-administration of TZD and GLP-1 helps regulate glucose homeostasis in Type II diabetic patients.
    Type: Grant
    Filed: June 6, 2000
    Date of Patent: August 18, 2009
    Assignee: Eli Lilly and Company
    Inventors: Fatima Emitsel Yakubu-Madus, Lawrence Edward Stramm, Louis Vignati, William Terry Johnson